RG
Redmile Group Portfolio holdings
AUM
$1.49B
Turnover
10.26%
1-Year Est. Return
208.7%
This Fund
S&P 500
This Quarter
Est. Return
+16.49%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$838M
AUM Growth
+$27.2M
(+3.4%)
Cap. Flow
-$59.8M
Cap. Flow
% of AUM
-7.14%
Top 10 Holdings %
Top 10 Hldgs %
41.9%
Holding
75
New
19
Increased
15
Reduced
20
Closed
20
Avg Time Held Equity + Options
0.3
years
Top 10 Avg Time Held Equity + Options
0.1
years
Top 20 Avg Time Held Equity + Options
0.2
years
Avg Time Held Equity only
0.3
years
Top 10 Avg Time Held Equity only
0.1
years
Top 20 Avg Time Held Equity only
0.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Agilent Technologies
A
|
+$44.5M |
| 2 |
Bausch Health
BHC
|
+$40.6M |
| 3 |
CSLT
CASTLIGHT HEALTH, INC.
CSLT
|
+$34.3M |
| 4 |
RAD
Rite Aid Corporation
RAD
|
+$23.2M |
| 5 |
HCA Healthcare
HCA
|
+$22.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$72.5M |
| 2 |
Gilead Sciences
GILD
|
+$48.6M |
| 3 |
Zimmer Biomet
ZBH
|
+$34.3M |
| 4 |
CELG
Celgene Corp
CELG
|
+$30.9M |
| 5 |
AstraZeneca
AZN
|
+$30.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.72% |
| 2 | Miscellaneous | 7.42% |
| 3 | Technology | 2.82% |
| 4 | Communication Services | 1.03% |
| 5 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
VanEck Pharmaceutical ETF
PPH
$1.05B
| $379K | 0.05% |
6,500
| – | – |
2013 Q2
3 quarters
|
|
52
VanEck Biotech ETF
BBH
$486M
| $292K | 0.03% |
+3,208
| New | +$312K |
2014 Q1
0 quarters
|
|
|
AGN
53
DELISTED
Allergan Inc
AGN
| $222K | 0.03% |
1,786
-197,941
| -99% | -$24.1M |
2013 Q2
3 quarters
|
|
|
AFFX
54
DELISTED
Affymetrix Inc
AFFX
| $96K | 0.01% |
+13,500
| New | +$109K |
2014 Q1
0 quarters
|
|
55
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $66K | 0.01% |
48
-119
| -71% | -$138K |
2013 Q4
1 quarter
|
|
56
Amarin Corp
AMRN
$245M
| – | – |
-199,410
| Closed | -$7.86M | – |
|
|
57
AstraZeneca
AZN
$251B
| – | – |
-511,120
| Closed | -$30.3M | – |
|
|
58
Gilead Sciences
GILD
$190B
| – | – |
-647,287
| Closed | -$48.6M | – |
|
59
iShares US Healthcare Providers ETF
IHF
$1.41B
| – | – |
-15,000
| Closed | -$280K | – |
|
60
Illumina
ILMN
$41B
| – | – |
-83,961
| Closed | -$9.04M | – |
|
61
Incyte
INCY
$22.6B
| – | – |
-448,998
| Closed | -$22.7M | – |
|
62
CALL
Merck
MRK
$364B
| – | – |
-296,060
| Closed | -$14.1M | – |
|
|
63
Merck
MRK
$364B
| – | – |
-2,515
| Closed | -$120K | – |
|
64
Pfizer
PFE
$166B
| – | – |
-564,944
| Closed | -$16.4M | – |
|
65
Regeneron Pharmaceuticals
REGN
$80.1B
| – | – |
-1,000
| Closed | -$275K | – |
|
66
Universal Health Services
UHS
$11B
| – | – |
-205,300
| Closed | -$16.7M | – |
|
|
67
Zimmer Biomet
ZBH
$17.5B
| – | – |
-378,669
| Closed | -$34.3M | – |
|
|
FMI
68
DELISTED
Foundation Medicine, Inc.
FMI
| – | – |
-110,092
| Closed | -$2.62M | – |
|
|
STJ
69
DELISTED
St Jude Medical
STJ
| – | – |
-213,164
| Closed | -$13.2M | – |
|
|
SIRO
70
DELISTED
SIRONA DENTAL SYSTEMS INC COM STK
SIRO
| – | – |
-124,425
| Closed | -$8.73M | – |
|
|
DYAX
71
DELISTED
DYAX CORPORATION
DYAX
| – | – |
-25,000
| Closed | -$188K | – |
|
|
TRNX
72
DELISTED
TORNIER N V SHARES (NLD)
TRNX
| – | – |
-487,577
| Closed | -$9.16M | – |
|
|
FRX
73
DELISTED
FOREST LABORATORIES INC
FRX
| – | – |
-228,100
| Closed | -$13.7M | – |
|
|
CELG
74
DELISTED
Celgene Corp
CELG
| – | – |
-366,036
| Closed | -$30.9M | – |
|
75
DELISTED
VCA Inc.
WOOF
| – | – |
-306,200
| Closed | -$9.6M | – |
|
Similar funds
FCM
MM
WA
ACB
LCS
GAM
MFWP
PMG
Redmile Group's Q1 2014 Portfolio in Review
As of Q1 2014, Redmile Group held 75 positions worth $838M, up 3.4% from $810M the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Redmile Group withdrew a net $59.8M in Q1 2014, closing 20 positions and reducing 20 holdings. Its most notable exit was Gilead Sciences, an estimated $48.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 86% a quarter earlier, followed by Miscellaneous and Technology.
Against the trend, Redmile Group opened a new position in Agilent Technologies worth $43.2M.
- Redmile Group's largest Q1 2014 buy was Agilent Technologies: 1,080,646 shares worth $43.2M.
- Redmile Group added most to HCA Healthcare in Q1 2014, an estimated $22.6M increase.
- Redmile Group's biggest Q1 2014 reduction was Intercept Pharmaceuticals, Inc., cutting an estimated $72.5M.
- Redmile Group fully exited Gilead Sciences in Q1 2014, selling an estimated $48.6M.
- Redmile Group's ten largest holdings make up 42% of its $838M portfolio in Q1 2014.
- Redmile Group opened 19 new positions and closed 20 in Q1 2014.
- Redmile Group's portfolio value rose 3.4% quarter-over-quarter to $838M.
Based on Redmile Group's 13F filing for Q1 2014, filed 15 May 2014.